The jubilation Americans felt about the speed with which Pfizer and BioNTech, Moderna, AstraZeneca and Oxford University, and other groups developed their respective versions of a vaccine for COVID-19 has met the cold, hard reality of just how complex supply chains can be.
On one hand we read about how Israel has vaccinated 20% of its population within three weeks. On the other hand we are confronted with record deaths from COVID-19 in the United States in the midst of a very slow start to the...